{
    "clinical_study": {
        "@rank": "168093", 
        "arm_group": {
            "arm_group_label": "Chlorambucil, Rituximab i.v., Rituximab s.c.", 
            "arm_group_type": "Experimental", 
            "description": "Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4).\nStarting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections)."
        }, 
        "brief_summary": {
            "textblock": "This is a single arm phase II study of Chlorambucil in combination with subcutaneous\n      Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with\n      histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of MALT type\n      arisen at any extranodal site, either de novo, or relapsed following local therapy\n      (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma)."
        }, 
        "brief_title": "This Trial is a Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma", 
        "completion_date": {
            "#text": "December 2025", 
            "@type": "Anticipated"
        }, 
        "condition": "MALT Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell, Marginal Zone"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study consists in three parts. In Part A (induction phase I) patients will be treated\n      with Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with\n      intravenous Rituximab 375mg/m2 on day 1 week 1 followed by subcutaneous Rituximab 1400mg on\n      days 8, 15 and 22 (day 1 of weeks 2, 3 and 4). After restaging (CT scan to be performed\n      during weeks 7-8, i.e. between d42 and d55), responding patients (CR, CRu, PR) and those\n      with stable disease will be treated in part B (induction phase II). In part B, starting from\n      d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days\n      (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day\n      1 of each 28-day cycle. After restaging (CT scan to be performed at the end of month 6)\n      responding patients and those with stable disease will be treated in part C. In Part C\n      (maintenance phase) patients will be treated with subcutaneous Rituximab 1400mg every two\n      months for 2 years (in total 12 injections). During maintenance phase, CT scans will be\n      performed every 12 months and patients responding or with stable disease will stay on\n      treatment for a total of two years as above reported."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically proven diagnosis of CD20-positive marginal zone B-cell lymphoma of\n             MALT type either de novo, or relapsed following local therapy (including surgery,\n             radiotherapy and antibiotics for H. pylori-positive gastric lymphoma) arisen at any\n             extranodal site 1.1 The following patients with gastric MALT Lymphoma can be entered:\n\n               -  H. pylori-negative cases, either de novo (non pre-treated) or at relapse\n                  following local therapy (i.e., surgery, radiotherapy or antibiotics).\n\n               -  H. pylori-positive cases at diagnosis, who failed antibiotic therapy, including\n\n                    -  Patients with clinical (endoscopic) and histological evidence of disease\n                       progression at any time post H. pylori eradication\n\n                    -  Stable disease with persistent lymphoma at \u2265 1 year post H. pylori\n                       eradication\n\n                    -  Relapse (without H. pylori re-infection), after a remission\n\n                    -  Patients who failed either first line antibiotics or further local\n                       treatment (surgery or radiotherapy) 1.2 Similar consideration may be\n                       applied to patients with ocular adnexal lymphoma treated with antibiotics.\n\n          2. Measurable or evaluable disease. Measurable disease in at least two perpendicular\n             dimensions on an imaging scan is defined as: lymph node or nodal mass bi-dimensional\n             measurement with > 1.5 cm in longest transverse diameter or the short diameter must\n             measure > 10 mm regardless of the longest transverse diameter.\n\n          3. Any stage (Ann Arbor I-IV) (see Appendix A)\n\n          4. Age \u2265 18\n\n          5. Life expectancy of at least 1 year\n\n          6. ECOG performance status 0-2 (see Appendix B)\n\n          7. Adequate bone marrow function (WBC >3.0x109/L, ANC >1.5x109/L, PLT >100x109/L),\n             unless due to lymphoma involvement\n\n          8. Adequate kidney (serum creatinine <1,5x upper normal) and liver function (ASAT/ALAT\n             <2,5 upper normal, total bilirubin <2,5x upper normal), unless due to lymphoma\n             involvement\n\n          9. For women of childbearing potential only: negative serum pregnancy test done within 7\n             days prior to study drugs administration or within 14 days if with a confirmatory\n             urine pregnancy test within 7 days prior to the first study drugs administration\n\n         10. Fertile male or female patients of childbearing potential and their partners must use\n             two forms of contraception during the study and for at least 12 months after the last\n             dose of subcutaneous rituximab.\n\n             For appropriate methods of contraception considered acceptable, see Appendix C.\n             Should a woman become pregnant or suspect she is pregnant while she or her partner\n             are participating in this study and for 12 months after study participation, the\n             patient should inform the treating physician immediately.\n\n             Female patients of childbearing potential are defined as follows:\n\n               -  Pre-menopausal women (patients with regular menstruation, patients after\n                  menarche with amenorrhea or irregular cycles, patients using a contraceptive\n                  method that precludes withdrawal bleeding\n\n               -  Women who have had tubal ligation\n\n             Female patients may be considered to NOT be of childbearing potential for the\n             following reasons:\n\n               -  The patient has undergone total abdominal hysterectomy with bilateral\n                  salpingo-oophorectomy or bilateral oophorectomy\n\n               -  The patient is medically confirmed to be menopausal (no menstrual period) for 24\n                  consecutive months\n\n         11. Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          1. Evidence of histologic transformation to a high grade lymphoma\n\n          2. Prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia\n             type 1 (CIN1) or localized non-melanomatous skin cancer\n\n          3. Prior chemotherapy\n\n          4. Prior immunotherapy with any anti-CD20 monoclonal antibody\n\n          5. Prior radiotherapy in the last 6 weeks\n\n          6. Use of corticosteroids during the last 28 days, unless prednisone chronically\n             administered at a dose <20 mg/day for indications other than lymphoma or\n             lymphoma-related symptoms\n\n          7. Evidence of clinically significant cardiac disease, as defined by history of\n             symptomatic ventricular arrhythmias, congestive heart failure or myocardial\n             infarction within 12 months before study entry\n\n          8. Evidence of symptomatic central nervous system (CNS) disease\n\n          9. Evidence of active opportunistic infections\n\n         10. Known HIV infection\n\n         11. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In\n             addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a\n             HBV DNA test will be performed and if positive the subject will be excluded\n\n         12. Positive serology for hepatitis C (HC) defined as a positive test for HCAb, confirmed\n             by HC RIBA immunoblot assay on the same sample.\n\n         13. Pregnant or lactating status\n\n         14. Any psychological, familial, sociological or geographical condition potentially\n             hampering compliance with the study protocol and follow-up schedule; those conditions\n             should be discussed with the patient before registration in the trial\n\n         15. Fertile men or women of childbearing potential who do not agree to use a highly\n             effective measure of contraception (such as oral contraceptives, intrauterine device\n             or barrier method of contraception in conjunction with spermicidal jelly or\n             surgically sterile) throughout the study and for at least 12 months after the last\n             dose of subcutaneous rituximab"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808599", 
            "org_study_id": "IELSG38"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chlorambucil, Rituximab i.v., Rituximab s.c.", 
                "intervention_name": "Chlorambucil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chlorambucil, Rituximab i.v., Rituximab s.c.", 
                "intervention_name": "Rituximab i.v.", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chlorambucil, Rituximab i.v., Rituximab s.c.", 
                "intervention_name": "Rituximab s.c.", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chlorambucil", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bellinzona", 
                    "country": "Switzerland", 
                    "zip": "6500"
                }, 
                "name": "IOSI - Oncology Institute of Southern Switzerland"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Chlorambucil in Combination With Subcutaneous Rituximab Followed by Maintenance Therapy With Subcutaneous Rituximab in Patients With Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma)", 
        "overall_contact": {
            "email": "ielsg@ticino.com", 
            "last_name": "Emanuele Zucca, MD", 
            "phone": "+41 91 811 9040"
        }, 
        "overall_contact_backup": {
            "email": "ielsg@ticino.com", 
            "last_name": "IELSG Operation Office"
        }, 
        "overall_official": {
            "affiliation": "IOSI Oncology Institute of Southern Switzerland", 
            "last_name": "Emanuele Zucca, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Switzerland: Ethikkommission", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Complete remission rate", 
            "safety_issue": "No", 
            "time_frame": "week 25"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808599"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response rate (Complete and partial remission rates) for all patients", 
                "measure": "Response Rate", 
                "safety_issue": "No", 
                "time_frame": "week 25"
            }, 
            {
                "measure": "Event-free-survival (EFS)", 
                "safety_issue": "No", 
                "time_frame": "at 5 years"
            }
        ], 
        "source": "International Extranodal Lymphoma Study Group (IELSG)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "International Extranodal Lymphoma Study Group (IELSG)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}